CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
In a new blog by Aisha Syeda, senior program manager at AHA, learn how you can participate in the first Better Health for Mothers and Babies Awareness Week,…
Blog
Every mother and baby deserves the opportunity for a healthy start. Hospitals and health systems help make that possible by providing care throughout pregnancy…
Headline
A report released Sept. 21 by the Centers for Disease Control and Prevention found improvements in mental health and dietary habits among U.S. high school…
Headline
In episode one of Frontiers, a special three-part podcast series from the AHA that examines maternal health in rural America, learn how rural hospital leaders…
Headline
Join the AHA’s Better Health for Mothers and Babies Initiative in observing NICU Awareness Month in September and NICU Awareness Day on Sept. 30. From Sept. 28…
Headline
A new infographic that is a part of the AHA’s Better Health for Mothers and Babies Initiative examines the many factors influencing child and adolescent health…